TCR-like Antibody Yeast Display Development Services
IMMUNE Platform Introduction
IMMUNE (Identifying Massive MHC Utilized Novel Epitopes) platform, developed by JWE, is a proprietary immune epitope analysis platform designed for the development and screening of TCR-like antibodies. It is based on a yeast-displayed HLA system, enabling efficient epitope identification and analysis.
| Platform Name | IMMUNE Platform |
|---|---|
| Platform Type | Proprietary immune epitope discovery and analysis platform |
| Platform ID | JWEPFM0001 |
Service Background
Therapeutic antibodies mainly target tumor cell surface markers, such as PD1. Short peptides inside tumor cells can be presented on the cell surface by MHC-I/MHC-II, forming MHC-peptide supercomplexes recognized by TCRs, triggering an immune response. Based on this, TCR-like antibodies can mimic TCR recognition and achieve immune activation and tumor cell killing by combining with CD3 antibodies.
TCR-like Antibody Development Services
Traditional TCR-like antibody development is challenging because MHC-peptide supercomplexes exist via non-covalent bonds, making stable preparation difficult. JWE combines yeast display technology to design and synthesize TCR-like antibody libraries with MHC specificity, enabling rapid development of antibodies against specific pMHC complexes.
Prebuilt Library Information
| MHC Type | Library Type | Screening Method | Amino Acid Mutations | Library Capacity | Antibody Format |
|---|---|---|---|---|---|
| HLA-A*02:01 | Yeast Display Library | FACS | 9 | 109 | scFv |
| HLA-A*03:01 | Yeast Display Library | FACS | 10 | 109 | scFv |
| HLA-A*11:01 | Yeast Display Library | FACS | 10 | 109 | scFv |
Service Workflow
| Step | Service Content | Timeline |
|---|---|---|
| Library Construction | High-fidelity PCR amplification of TCR-like antibody genes and cloning into yeast display vectors to construct antibody libraries with high insertion rate and capacity | 2-3 weeks |
| Library Screening | Screen specific antibodies using fluorescently labeled proteins and FACS, cluster by affinity, and perform single-clone validation | 3-4 weeks |
| Antibody Validation | Recombinant antibody expression, purification, and quantification; ELISA/BLI to validate binding ability and affinity | 4-6 weeks |
Service Advantages
- No animal immunization required, reducing ethical concerns and experimental complexity
- High library diversity with insertion and positivity rates exceeding 90%
- FACS allows clustering of antibodies with different affinities
- Customizable services to meet research and drug development needs
- Combined with IMMUNE Platform, enables qualitative and quantitative analysis of HLA-peptide binding
